Impaired Platelet Function among Platelet Donors

Abstract

Summary Background: Platelet transfusions are effective for the prevention and treatment of bleeding in patients with disorders of platelet number and/or function. In recent years plateletpheresis concentrates have outnumbered pooled platelet concentrates, albeit with significant differences between nations. Thus, the platelet quality of individual donors has become increasingly important. The aim of this study was to gain an estimate for the prevalence of impaired platelet function among platelet donors. Study design and methods: We determined the inter-donor variability in platelet plug formation with a PFA-100 analyzer, the prevalence of impaired thromboxane formation, and effects of the density in alpha2 integrin polymorphism and density. Results: (i) Collagen-epinephrine induced closure time (CEPI-CT) showed a great inter-subject variability in platelet donors and was higher than in healthy controls (p = 0.008). One-fifth of donors had abnormal CEPI-CT values and 11% exceeded >300 s (max measurable value). (ii) Decreased serum thromboxane B2 levels were found in 9% of all donors, compatible with surreptitious intake of cyclooxygenase inhibitors or with an aspirin-like defect. CEPI-CT correlated inversely with TxB2-levels in donors and controls. (iii) The density of the alpha2-integrin correlated negatively with CEPI-CT and CADP-CT values in controls, but was not responsible for the observed impaired platelet function in donors. (iv) Finally, the ABO blood group system modulates closure times. Conclusion: In sum, a large number of platelet donors present with prolonged closure times. Decreased thromboxane formation and frequent platelet donation partly account for this observation. Abbreviations: 807 CC/CT/TT polymorphisms of the alpha2-integrin gene, CD36… GPIIIb, an alternative collagen receptor, CD42b… GpIb, the von Willebrand receptor, CD49b… alpha2-integrin, subunit of the main collagen receptor, CADP-CT… collagen adenosine diphosphate induced closure time, CEPI-CT… collagen/epinephrine induced closure time, PFA-100… platelet function analyzer, vWF-Ag… von Willebrand factor antigen, TXB2… thromboxane B2

A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia–reperfusion injury

“…It is also well known that EPO can cause thrombosis and therefore tissue injury (40). Even a single exposure of normal humans to EPO causes a dose-dependent increase in E-selectin within 2 days, which is consistent with significant endothelial cell activation (41). Similar responses have also been documented for other markers associated with thrombosis, e.g., P-selectin, and in vitro studies confirm direct and rapid prothrombotic effects of EPO on the endothelium (42).…”

New Insights into Nephrogenic Systemic Fibrosis

“…EPO is a potent cytokine with stimulatory effects on vascular endothelium, 43 smooth muscle cells, 44,45 and platelets. 46 EPO administration induces a release of vasoactive factors such as monocyte chemoattractant protein-1, 45,47 endothelin-1, 48 thromboxane A2, and selectin. 46,49 It can also induce endothelial dysfunction by inhibiting dimethylarginine dimethylaminohydrolase, thereby increasing asymmetric dimethyl arginine.…”

“…46 EPO administration induces a release of vasoactive factors such as monocyte chemoattractant protein-1, 45,47 endothelin-1, 48 thromboxane A2, and selectin. 46,49 It can also induce endothelial dysfunction by inhibiting dimethylarginine dimethylaminohydrolase, thereby increasing asymmetric dimethyl arginine. 50 Furthermore, EPO is a potent stimulant of endothelial and progenitor cell proliferation, 51,52 as well as wound-healing responses 53 that are reminiscent of histologic 45,47 might also contribute to the fibrogenesis seen in NSF.…”

Reparixin, a Specific Interleukin-8 Inhibitor, Has No Effects on Inflammation during Endotoxemia

“…We determined prothrombin fragment (F 1 + 2 ) by an enzyme immunoassay (Behring, Marburg, Germany) to examine whether the blockade of IL-8 inhibits thrombin formation. We measured serum thromboxane B 2 levels as previously described (10), to evaluate if the accumulation of the reparixin metabolite ibuprofen (C ss= 4mg/L) is sufficient to inhibit the cyclooxygenase pathway. Blood counts were performed with a cell counter (Sysmex, Milton Keynes, UK).…”